Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLBP-037
- Development stage
- Preclinical
- Lead developer
- HLB Pharma
- Administration
- Parenteral
01
Overview
HLBP-037 is a preclinical-stage long-acting injectable (LAI) candidate being developed by HLB Pharma for the treatment of dementia. The drug utilizes the company's proprietary SMEB (Sustained-release Microsphere Embedding) technology, which is designed to encapsulate active pharmaceutical ingredients within biodegradable polymer microspheres to enable controlled, long-term release. This formulation platform aims to improve medication adherence and maintain stable plasma concentrations in patients with cognitive impairment, potentially reducing the burden of daily oral dosing. While the specific active pharmaceutical ingredient (API) and molecular target have not been publicly disclosed, the program is a key component of HLB Pharma's central nervous system (CNS) pipeline.
Beyond the preview
Go deeper on HLBP-037.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLBP-037.